{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:08:56Z","timestamp":1783591736558,"version":"3.55.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.01233","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T04:22:31Z","timestamp":1527826951000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":43,"title":["Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim\u2013Chester Disease"],"prefix":"10.3389","volume":"9","author":[{"given":"Alessandro","family":"Tomelleri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Cavalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Campochiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"D\u2019Aliberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moreno","family":"Tresoldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Dagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,6,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ejim.2015.03.004","article-title":"Erdheim-Chester disease","volume":"26","author":"Campochiaro","year":"2015","journal-title":"Eur J Intern Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e3697","DOI":"10.1097\/MD.0000000000003697","article-title":"Erdheim-Chester disease with multiorgan involvement, following polycythemia vera","volume":"95","author":"Iurlo","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1136\/annrheumdis-2013-203685","article-title":"Diagnosing Erdheim\u2013Chester disease","volume":"72","author":"Cavalli","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejim.2014.06.015","article-title":"An enlightening scan","volume":"26","author":"Canziani","year":"2015","journal-title":"Eur J Intern Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/annrheumdis-2012-202542","article-title":"The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases","volume":"72","author":"Cavalli","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1182\/blood-2010-06-294108","article-title":"CNS involvement and treatment with interferon-\u03b1 are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients","volume":"117","author":"Arnaud","year":"2011","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1182\/blood-2014-03-561381","article-title":"Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease","volume":"124","author":"Diamond","year":"2014","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e1181244","DOI":"10.1080\/2162402X.2016.1181244","article-title":"Plasma chromogranin A as a marker of cardiovascular involvement in Erdheim\u2013Chester disease","volume":"5","author":"Ferrero","year":"2016","journal-title":"Oncoimmunology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00415-017-8692-8","article-title":"Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim-Chester disease","volume":"265","author":"Chiapparini","year":"2017","journal-title":"J Neurol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3389\/fimmu.2014.00281","article-title":"Oncogene-induced senescence as a new mechanism of disease: the paradigm of Erdheim-Chester disease","volume":"5","author":"Cavalli","year":"2014","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21678707.2017.1285226","article-title":"Advances in potential targeted therapies for Erdheim-Chester disease","volume":"5","author":"Cavalli","year":"2017","journal-title":"Expert Opin Orphan Drugs"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1440929","article-title":"The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease","author":"Pacini","year":"2018","journal-title":"Oncoimmunology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e1318237","DOI":"10.1080\/2162402X.2017.1318237","article-title":"Tocilizumab in patients with multisystem Erdheim\u2013Chester disease","volume":"6","author":"Berti","year":"2017","journal-title":"Oncoimmunology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/rheumatology\/ket246","article-title":"TNF-\u03b1 in Erdheim-Chester disease pericardial effusion promotes endothelial leakage in vitro and is neutralized by infliximab","volume":"53","author":"Ferrero","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/j.ijcard.2013.12.137","article-title":"Formation of the inflammasome in acute myocarditis","volume":"171","author":"Toldo","year":"2014","journal-title":"Int J Cardiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1113\/expphysiol.2012.069021","article-title":"The heart on fire: inflammasome and cardiomyopathy","volume":"98","author":"Abbate","year":"2013","journal-title":"Exp Physiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3389\/fimmu.2017.00131","article-title":"Interleukin-1 receptor blockade rescues myocarditis-associated end-stage heart failure","volume":"8","author":"Cavalli","year":"2017","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3109\/03009742.2014.992949","article-title":"Efficacy and safety of biological agents in adult-onset Still\u2019s disease","volume":"44","author":"Cavalli","year":"2015","journal-title":"Scand J Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1164\/rccm.201412-2150LE","article-title":"Treating pulmonary silicosis by blocking interleukin 1","volume":"191","author":"Cavalli","year":"2015","journal-title":"Am J Resp Crit Care Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1093\/rheumatology\/kev269","article-title":"Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies","volume":"54","author":"Cavalli","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3389\/fphar.2017.00369","article-title":"Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset Still\u2019s disease: a multicentre retrospective observational study","volume":"8","author":"Colafrancesco","year":"2017","journal-title":"Front Pharmacol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e751","DOI":"10.1097\/CCM.0000000000001654","article-title":"Treating life-threatening myocarditis by blocking interleukin-1","volume":"44","author":"Cavalli","year":"2016","journal-title":"Crit Care Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1001\/jama.2016.15826","article-title":"Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial","volume":"316","author":"Brucato","year":"2016","journal-title":"JAMA"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1136\/annrheumdis-2013-204924","article-title":"BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease","volume":"74","author":"Cangi","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"bcr2015212483","DOI":"10.1136\/bcr-2015-212483","article-title":"Recurrent pericardial effusion and tamponade in a patient with Erdheim-Chester disease (ECD)","volume":"2015","author":"Mishra","year":"2015","journal-title":"BMJ Case Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/14397595.2014.905235","article-title":"Rapid progression to cardiac tamponade in Erdheim\u2013Chester disease despite treatment with interferon alpha","volume":"3","author":"Nakhleh","year":"2014","journal-title":"Mod Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1182\/blood-2012-07-446286","article-title":"Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation","volume":"121","author":"Haroche","year":"2013","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e286","DOI":"10.1200\/JCO.2012.41.9911","article-title":"Tumor necrosis factor \u03b1 as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab","volume":"30","author":"Dagna","year":"2012","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jbspin.2013.06.013","article-title":"Successful treatment of Erdheim-Chester disease by interleukin-1 receptor antagonist protein","volume":"81","author":"Courcoul","year":"2014","journal-title":"Joint Bone Spine"},{"key":"B30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrcardio.2015.115","article-title":"Recurrent pericarditis: new and emerging therapeutic options","volume":"13","author":"Imazio","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1136\/annrheumdis-2014-205990","article-title":"Anakinra for the management of resistant idiopathic recurrent pericarditis. Initial experience in 10 adult cases","volume":"73","author":"Lazaros","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1073\/pnas.1619011114","article-title":"Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance","volume":"114","author":"Cavalli","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B33","first-page":"S-155","article-title":"Cardiovascular manifestations of Erdheim-Chester disease","volume":"33","author":"Berti","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1182\/blood-2016-06-725143","article-title":"Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester disease","volume":"128","author":"Diamond","year":"2016","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1016\/j.ijcard.2013.04.057","article-title":"Erdheim-Chester disease with cardiac involvement successfully treated with anakinra","volume":"167","author":"Killu","year":"2013","journal-title":"Int J Cardiol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.autrev.2012.07.023","article-title":"Recurrent pericarditis: autoimmune or autoinflammatory?","volume":"12","author":"Maestroni","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","article-title":"Interleukin-1 in the pathogenesis and treatment of inflammatory diseases","volume":"117","author":"Dinarello","year":"2011","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1093\/rheumatology\/kew325","article-title":"Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation","volume":"55","author":"Cavalli","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/imr.12605","article-title":"Suppression of inflammation and acquired immunity by IL-37","volume":"281","author":"Cavalli","year":"2018","journal-title":"Immunol Rev"},{"key":"B40","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"B41","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.cell.2010.03.002","article-title":"Autoinflammatory disease reloaded: a clinical perspective","volume":"140","author":"Kastner","year":"2010","journal-title":"Cell"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","article-title":"2015 ESC guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and management of pericardial diseases of the European Society of Cardiology (ESC)endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"36","author":"Adler","year":"2015","journal-title":"Eur Heart J"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01233\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T04:22:32Z","timestamp":1527826952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01233\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2018.01233"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.01233","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,1]]},"article-number":"1233"}}